AbbVie: Glioblastoma trials
The registry lists 11 Glioblastoma studies with AbbVie as lead sponsor. 0 are open to participants now and 4 have results posted.
Phase 1 7Phase 2 3Phase 3 2No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- UNITE Study: Understanding New Interventions With GBM ThErapyTerminatedNCT03419403Phase 3Results posted
- Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid TumorsTerminatedNCT02709889Phase 1/2Results posted
- A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) AmplificationCompletedNCT02573324Phase 3Results posted
- Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade GliomasCompletedNCT02343406Phase 2Results posted
- A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)CompletedNCT03234712Phase 1
- Expanded Access to ABT-414No longer availableNCT03123952
- Study Evaluating ABT-414 in Japanese Subjects With Malignant GliomaCompletedNCT02590263Phase 1/2
- A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor ReceptorTerminatedNCT02365662Phase 1
- Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma MultiformeCompletedNCT01800695Phase 1
- Study of Motexafin Gadolinium and Docetaxel for Advanced CancerCompletedNCT00120939Phase 1
- A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant GliomasCompletedNCT00080054Phase 1